INTRODUCTION
The 9th International AIDS Economics Network (IAEN) pre-conference took place on 15-16 July 2016 and was hosted in partnership with the Bill and Melinda Gates Foundation, IAEN, HEARD, UNAIDS, the World Bank, the University of KwaZulu-Natal and Sida/Norad. The theme of the pre-conference was 'Investing in sustainable responses to HIV and AIDS' and preceded the International AIDS Conference held in Durban on 18-22 July 2016.
This two-day pre-conference considered practical solutions to financing the epidemic in the postMDGs era. While there are a number of initiatives globally working towards solutions, this preconference served a special purpose in bringing together economic decision-makers, researchers and stakeholders. These included Ministers of Finance and Health, leading activists, practitioners and scholars who have a shared understanding of the key issues and challenges, and through discussion, we hoped to develop real options for sustainable financing for AIDS.
The pre-conference included presentations of specially commissioned papers on key questions that explored innovative, country-led approaches for supporting affected countries and to prioritise, sustain and lead their national investments in HIV and AIDS responses. These were put forward for consideration and presentations by economic researchers funded by the Bill and Melinda Gates Foundation to conduct analyses in their own countries (Uganda, Kenya, Tanzania, Malawi, and Zambia). Papers selected from an open call were presented in thematic roundtable discussions/working groups/break away groups, and showcased as abstracts and posters. Open Call Contributions were based on emerging evidence and recent lessons from HIV and economic analyses, with contributions sought from theorists, analysts, practitioners and affected communities to explore new options, models and partnerships for financing the future of the epidemicparticularly in low and middle income countries. Papers were fed into an issues paper to inform the plenary session. The related research identified ways to create, optimise, and sustain fiscal space for HIV investment domestically, as well as explore innovative national and international financing mechanisms able to leverage allocated funds.
Dr Steven Forsythe President: International AIDS Economics Network 9th International AIDS Economics Network Pre-conference
On gender and cultural issues that impede the ending of AIDS, a majority of girls worldwide experience sexual violence and, for many young women, their first sexual experience is rape. To address this, it is necessary to meet and understand young people and to reach them in effective ways. It is now the millennials who are to assert that authority.
Ambassador Birx also noted the importance of testing men and called on delegates to ask 'how can we reach men?' Ambassador Birx announced that there are new PEPFAR targets for 2017 and noted that these targets called for the expansion of ART and more effective testing. Other targets include an increase of efficiencies and savings in financing the end of the illness, and doubling the amount of
Critical assessment
The key messages of the session, from both delegates and researchers, addressed the concern that flat funding in the AIDS response would negatively impact the ability to eradicate the disease. Researchers called for a more sustainable, efficient and investment based economic response, which relies on the domestic resources of the affected countries, rather than continued dependence on first world funding. This trend in health economics marks a new era for recognising the potential for growth and development beyond healthcare in the intended regions. Whilst the research addresses sustainable and long-term health care for those infected, the intention of health economist delegates is to provide sustainable development and growth. This is seen as a contribution to the overall Sustainable Development Goals (SDGs) mapped out by the joint UN nations as a target for the 2030 agenda. Researchers and policy makers who spoke at the session called for reforms in health and financial administration, as the current policies hinder a sustainable and targeted AIDS response. 
PLENARY SESSION 1 Speakers

Critical assessment
Key challenges regarding allocative efficiency analyses include:  assumptions about relationships between costs, outcomes and impact;  individual level efficacy vs population level, real life effectiveness;  coordination of allocative efficiency TA to countries;  allocative efficiency and technical efficiency inter-play; and,  service integration makes HIV AE analyses less meaningful.
Traditional domestic financing schemes are insufficient to meet the needs. There is need of sustained (and increasing) funding from international sources in addition to domestic funding.
PLENARY SESSION 3
The Global Health Cost Consortium (GHCC)
Robust estimates of costing information are very important for decision making with regards to economies of scope and scale, as well as quality and efficiency, and therefore crucial to plan for the future of health. The question arises whether enough costing information exists. Costing information is scarce for a number of reasons:
There is missing information.  Information is scattered.  It differs largely across contexts and geographic settings.  Since there is no standard of reporting, comparisons are impossible.
Due to the vast amounts of costing information needed and the limited resources available, it would not be possible to cost out all interventions in all countries. However, there are many costing studies in existence, as well as many researchers, and an environment for collaboration. Thus an opportunity emerges.
Hence the development of the Global Health Cost Consortium (GHCC) with the primary activities as follows. First, to extract data from selected published costing studies, to standardize data and improve where possible, and to compile this costing data. Second, to collect, compile and report on the methods used to obtain costing information. Third, to analyze the cost data so that any gaps found are filled by collecting high quality raw primary data. Lastly, to develop the tools necessary to access and visualize the cost data. What this project strives to achieve is the generation of a dataset of datasets by combining costing information from many studies to obtain the most robust estimates that cannot be found in one study. 
Key themes
Costing studies and database development are needed for efficient planning and decision making in HIV/AIDS prevention, treatment and care. Collaboration of diverse stakeholders and the integration of structural interventions focused on vulnerable populations are necessary.
Highlights
In most low and middle income countries, planners and decision makers do not have access to costing repository databases. There is a need to integrate data and continuously maintain those databases as there could be standard variations. Use easy to interpret costing measurements to bring more funders on board. Increase in domestic resources towards HIV/AIDS is ideal, but may be limited by low level of domestic income sustainability.
Critical Assessment
There has been a greater focus on treatment and care, and less on structural prevention measures. Response in some cases is not based on evidence. Infections in adults is not going down in some populations.
There is a need to:  overcome prevention barriers by understanding them;  improve the demand for HIV/AIDS services by men;  sustain retention for all users of HIV/AIDS services; competition -instead of competing, the HIV response might consider co-investing in SDGs to ensure they reach optimal scale and enhance the efficiency of HIV treatment and prevention efforts. Dr Zoe McLaren observed that the availability of ART in South Africa increased attention to TB screening and drew new patients into the health care system. 
Summary
Ms Marelize Gorgens presented a summary of the work of the HIV Economics reference group's technical working group on allocative efficiency. The work of this technical working group and the tools presented in this session are vital in the context of flat funding for HIV, the other development challenges faced by countries, especially in southern and eastern Africa.
Highlights
An overview of work products was presented. These included:  Inventory of HIV allocative efficiency tools which enable users to compare different approaches to allocative efficiency analyses, and select suitable tools for generating the information they require.  A fit-for-purpose assessment of the main allocative efficiency tools which will help users to understand the most suitable tool for different contexts and types of analysis.  A case study of a real life example of an allocative efficiency analysis from Sudan.  A case study of HIV service integration into UHC in Indonesia.  A model in development with the University of York This is currently a concept paper on using HIV allocative efficiency models in UHC benefits package determination.
Details of the products can be found at the Economic Reference Group website: www.hiv-erg.com
Critical assessment
This session was a good opportunity for economists, researchers, implementers and policy makers to bring themselves up to speed with the work currently being undertaken by the Economic Reference Group, and engage with some of the most current ways of thinking about the allocation of funding for HIV. This work is timely and fits in well with the current global agenda which is to increase the efficiency of HIV programmes, especially in an era where resources are becoming increasingly limited and contested, not only for HIV but for health more generally. However, models that are intended to inform allocation decisions need to be used with caution and a good understanding of context. Allocative efficiency tools are highly dependent on the quality of the data used in the analysis, and the validity of the assumptions used to parametrize the models. Thus increasing the quality of data will be vital for the tools to have maximum impact in guiding policy and implementation of shifts in focus and funding. There were five presentations in this session. The first session looked at whether South Africa should integrate HIV financing into a single fund, and a national health insurance (NHI). The question 'and if so then how?' was asked. A framework-driven approach is necessary to facilitate policy dialogue about sustainable financing. HIV budgets are large and growing faster than the rest of the primary health care and overall DOH budgets in South Africa. Since HIV spending crowds out other important spending in health, and particularly in light of the hope to reach 90-90-90 by 2020, money allocated, would need to be pooled into a single fund. But how could this process be integrated? A suggestion is to use the Conditional Grant as the seed for NHI. There are however other integrative responses.
The second presentation looked at how to spend more, to spend less in terms of a unit cost of a tailored demand creation intervention to increase uptake of Voluntary Medical Male Circumcision (VMMC). To generate demand towards VMMC in Rural Tanzania, a Discrete Choice Experiment (DCE) was conducted. Since there is a large uptake of VMMC (mainly amongst adolescents), it is important to determine how to increase demand amongst adults. The results attempted to observe preferences for different attributes of VMMC to see what is significantly preferred.
The third presentation looked at the future financing of health. To sustain the response to HIV, Global Fund has 3 main areas of spending: 1) supplying global public goods such as new product development, 2) managing cross boarder externalities such as disease spread, and 3) exercising leadership in terms of aid effectiveness. These are all country-specific functions with regards to providing support such as assisting during transitions from low to middle income countries.
The fourth presentation looked at the application of payment for results from a case study in Ukraine, looking at opiate substitution treatment (OST) in the global fund HIV grant. OST uses methadone instead of injecting for drug users. The government and NGOs incentivized injecting drug users to stay on OST for 6 to 12 months. The study found that results improved when payments were offered. This can be applied since providing incentives increases results.
The final presentation looked at modelling the cost and impact of interventions for early infant diagnosis of HIV in South Africa. If HIV tests are performed too late after birth, then treatment is significantly delayed and mortality increases. There is new technology, but is it feasible? The case study compared the standard of care of PCR test to point of care (POC). The study was performed using a top-down, provider perspective of 360,000 babies. Costs were lower for PCR, but there was a large amount of treatment for POC, which results in large expenses. There is however, still an argument for POC. Due to the large number on treatment, there is an increase in the survival rate.
There is also a decrease loss to follow up as well as less wastage in POC when compared to PCR. Therefore, despite high start-up costs, POC saves in efficiency. 
PARALLEL SESSION C Speakers
Summary
Ms Cathy Barker presented two presentations in this session on behalf of The Palladium Group. The first of which looked at the global 90-90-90 treatment targets and the call for rapid scale up of ART for HIV. Scaling up ART to ambitious levels has significant cost implications, but few studies have projected the global resources needed or available for ART. We modelled the number of people eligible for and receiving ART from 2015 to 2020 in 97 countries, along with the facility-level resources required, taking into account context-specific data on treatment failure and regimen switching, and recent commodity prices paid by region. Current coverage and future scale-up patterns were based on country-specific data. Simulated annual numbers of individuals on treatment were derived from three scenarios: (1) continuation of countries' current ART eligibility policies, (2) universal adoption of the WHO 2013 eligibility guidelines, and (3) expanded eligibility as per the WHO 2015 guidelines and meeting the 90-90-90 ART targets. We modeled uncertainty in the annual costs of antiretroviral drugs, laboratory tests, and facility-level personnel and overhead, while assuming efficiency gain in site-level costs and uncertain annual declines in ARV and laboratory commodity costs based on recent trends. We compared the estimated financial requirements to estimated funding available from PEPFAR, the Global Fund, and domestic sources, using recent data. Conclusions: Across all scenarios, projected ART resource needs are greater than those available, even with ambitious assumptions for domestic contributions and modeled efficiency gains. Our estimates suggest that the financial sustainability of scaling up ART globally may be at risk without either additional resource mobilization or efficiency and effectiveness gains.
Ms Teresa Guthrie's presentation looked at the South African government's increasing allocation of resources for HIV. In order to better assess past spending and determine the most impactful future allocations across ten interventions, the South African government and UNAIDS undertook an Investment Case. The study concluded that tracking provided an innovative approach to consolidating data from domestic and international funders into a database compatible with public finance data, potentially enabling routine and real-time analysis for use by the government and partners.
Ms Sarah Khanakwa's presentation focused on institutionalising national aids resource tracking in Uganda. Funding sources in the country included government, development partners and private contributions which increased exponentially from around US$40million in 2003/04 to nearly US$360million in 2012/13 in Uganda (GARPR, 2014) . Despite this the mechanisms and capacity for tracking efficiency and effectiveness in the utilization of HIV/AIDS resources remain weak and uncoordinated with data deficiencies particularly in relation to consistency, timeliness and accuracy at all levels. Lessons learned from the study included linking HIV resource tracking data with existing Health M&E Systems could provide synergies for more effective assessment and a more detailed picture of funding flows all the way from funding source down to facility level expenditure. Study recommendations included making NASA a routine and active component of the country's health system in Uganda to ensure; regular reporting of financial data related to the amounts, channels used to access, thematic disaggregation, ultimate beneficiary population, the different factors of production employed and the allocation and use of the funds.
The second presentation by Ms Cathy Barker looked at the assessment of the need for and related costs of human resources for HIV in Tanzania, 2016-2020. Although donors fund the majority of the costs of Tanzania's HIV response, the government of Tanzania (GoT) substantially funds human resources for health (HRH). Exact estimates of the relative share of GoT funding are difficult to obtain, including from national health accounts, due to poor knowledge of the monetary value of government spending on the labor component of HIV services. At constant productivity, this spending will need to rise to meet ambitious GoT targets. Establishing the labour intensity of HIV services is a critical first step before estimating the need for HRH or monetizing the GoT contribution. The study concluded that recent national guidelines in Tanzania recommend HIV service delivery models that are more efficient, especially for ART. HRH labor intensity for HIV may decrease as more health facilities adhere to national guidelines. The HRH time saved per patient, per year may allow for more HIV services or other critical health services to be provided, given the projected workforce. Across scenarios for 2016, the GoT contribution for HRH costs, net of constant levels of PEPFAR support for salary and benefits, could be 47─108% of the projected external funding for HIV commodities (US$121 million). 
PARALLEL SESSION D Speakers
Summary
This session, moderated by Sergio Bautista from the National Institute of Public Health in Mexico, focused on demand relating to condom sales, distance travelled to nearest health facility and linkage to care, use of informal payments for health care, integrated production and prospects for resource mobilisation to fund HIV responses.
Highlights
 Demand stimulation tools affect demand products differently: No one-size fits all marketing for new products.  A need to improve payment schemes for health workers to better fit the remuneration to the actual workload (e.g. through pay-for-performance). Increasing salaries alone may not be effective. An additional advantage is implementing task shifting in HIV-care, particularly in a context where the number of doctors is low compared to the growing number of PLWHA  The ORPHEA data shows evidence of economies of scope. Big scale effects -particularly for small facilities. Next steps: Identification of policy variables and other "cost shifters", and analysing the relationship between 'quality' and costs variation.  Among women, living one additional kilometre away from the nearest clinic was associated with: 6.6% reduction in the rate of linkage to care, 6.5% reduction in the rate of ART initiation, 5.4% reduction in rate of retention on ART. Conditional on linkage to care, there was no association between distance and ART initiation and retention. There was also no association between distance and care-seeking for men. Sex*distance interaction was significant at all stages. Distance matters, but only for women. There was further work needed to understand differential patterns by sex.
Critical Assessment
Countries in resource-constrained settings are facing a plateau in donor resources. Some ways in which they may still achieve their current ART targets and long term sustainability in their HIV responses include (i) promoting macroeconomic stability and growth to protect and increase fiscal space for HIV and health overall; (ii) strengthening the tax administration system to reach tax capacity and increase fiscal space for HIV and health, and; (iii) promote value for money in HRH through improved training, task shifting, and salary structure. 
Points of convergence
The Honorable Minister of Health Botswana opened the panel discussion, facilitated by Professor Shela Tlou (UNAIDS) and Professor Nana Poku (HEARD), with a short overview arising from a prior meeting organized by HEARD, UNAIDS and SIDA in February at Ditchley (UK). Drawing from the Ditchley meeting (also attended by all the Ministers on the panel), she highlighted three contextual issues to frame the discussions: First, recognition that funding for HIV and AIDS is now sited within the very large and encompassing Sustainable Development Goals; with cost implications of any combination of the larger agenda issues (climate change; ending poverty in all its forms) sharpening the unavoidable political differences over prioritization (both human and fiscal).
Second, while the logic of front loading resources to achieve 'Fast Track' targets was indisputable, the call by UNAIDS for greatly increased funding must be set against the reality of donor intentions and domestic prioritizations. It seems likely that at best, funding levels will flat-line and perhaps suffer a decline of as much as 10 per cent over the next five years. As such the role of efficiency, prioritization and increase in domestic financing becomes even more pressing; with a dialogue with Ministries of Finance -a priority.
Third, and allied to the second element, is the imperative of establishing or greatly extending and improving Universal Health Coverage (UHC). Although the political commitment to the SDGs was acknowledged their impacts are likely to be less immediately pressing than either the UNAIDS agenda and how African states might best ensure that no ground is lost to AIDS; and reconciling the costs of expanding the fight against AIDS to the demands of UHC.
The three observations highlight the enduring, fundamental tension at the heart of the global AIDS response. The first is 'fair share': how much can low -and middle-income countries be expected to contribute to their HIV and AIDS programs, given the rapid economic growth across the regions? The second is 'global solidarity' -the responsibility and capacity donors have to honor their existing commitments and continue to contribute financially to the fight against HIV and AIDS.
Panelists agreed that the call for improved programmatic efficiencies is much to be lauded (and indeed, expected); however, because of the success to date of ART-and the emphasis on donordirected (as well as financed) biomedical interventions more generally, we have lost sight of something quite fundamental. The most important efficiency that can be achieved is to greatly reduce the number of new infections. Historically, we know that the steepest declines in new HIV infections have arisen from behavioral change, but identifying what is most effective has proved difficult to identify and is very likely to be highly context-dependent.
This makes more research into effective and enduring behavioral change for the purpose of reducing infections a first-order priority. A further, unintended and unfortunate consequence of the rapid scale-up of ART regimes has been the debilitation of community (often voluntary) programs and responses, especially those dedicated to prevention. It will not be an easy matter to revitalize or reconstitute them; and the voluntary ethos might not be recoverable.
Key Messages
Accelerating Fast Track implementation in the next five years is key to preserving the gains made against the epidemic and to prevent it from rebounding in the years ahead. For this purpose, a clarification of country-by-country fiscal gaps (read investment cases) is essential for transitional planning, not least so that whatever sums can be secured by country-level financial innovation and efficiency savings can be prioritized and allocated effectively. It was agreed that such an approach would require a differentiated methodology to reflect country contexts and needs. A country scorecard will be necessary to track Fast Track implementation and strengthen accountability and transparency.
The 'fair share' principle is not exhausted by African states absorbing an ever-larger portion of AIDS expenditure, and nor did the Doha Declaration signal the end of 'global solidarity.' Both will need to be invoked at the difficult junctures we will inevitably face. In particular, a watchful eye needs to be kept on new trade agreements that would place new obstacles in the way of African states securing affordable access to improved ARVs as well as second-and third-line treatments. And perhaps 'global solidarity' begins at home, efficiency gains, the creation of fiscal space and domestic resources, stronger governance mechanisms and innovate forms of funding will all be required.
It is important to capitalize on the vibrant community movement and results generated through the AIDS response to access treatment, reach with HIV prevention and treatment services the key populations, and more importantly to reduce stigma and address the human rights and social justice as part of the response. Countries need to explore community involvement and its role in the UHC as interface between key populations and health services, and explore potential social contracting of community organizations based on a results and accountability framework.
Next steps
Ministers proposed the establishment of an East and Southern African Policy Group for HIV Financing, led by the Ministers of Health of Botswana, Namibia, Zimbabwe and Lesotho. The Policy Group is to be mandated to pursue three key priorities in the region: a) Support Country HIV Financing Dialogue; b) Engage in increased efficiencies through pooled regional procurement systems; c) Lead dialogue and leverage partnership with the Ministers of Finance.
A secretariat is to be established within HEARD, jointly managed with UNAIDS, with the purpose of following up similar political dialogues at country level with Ministers of Finance, Parliamentarians, Central Banks and partners to contextualize the means to a more effective and sustainable AIDS response. .5% respectively). Additionally, the cost per patient per facility decreases as the size of facility increases. The study revealed that there was a wide variability in the average annual ART costs/patient. Results from the study will help design intervention to improve efficiency in the delivery of comprehensive HIV services in Nigeria.
PARALLEL SESSION E
Mr John Fieno's presentation's study objective was to measure the efficiency of HIV/AIDS spending in Kenya with respect to HIV incidence rate, AIDS-related mortality, antiretroviral treatment (ART) coverage, and maternal prophylaxis coverage. The study focused on Kenya and utilised data collected from the Kenya National AIDS spending assessment reports for the financial years 2009/2010 to 2011/2012, Kenya HIV estimates 2014 and Kenya HIV county profiles 2014. The data is mainly analysed using the Stochastic Frontier Analysis (SFA) technique. Preliminary results indicated that HIV/AIDs spending is significant in influencing HIV incidence rate, AIDS-related mortality and ART coverage. Dr Awiti concluded that it was crucial to address the endogeneity problem of HIV/AIDS spending before commenting on its efficiency implications. Dr Fieno's study methodology included an incremental cost-effectiveness ratio (ICER) which was used to compare each intervention with the default of a standard clinical approach to HAART with no CBART program. Results revealed that both CBART interventions were highly cost-effective: the ICER for adherence clubs was $82 per HIV infection averted, and the ICER for community level case management was $882. Sensitivity analysis showed that both interventions remained cost-effectiveness across a wide range of costs and levels of efficacy.
The last presentation for the session focused on the HIV epidemic in Mexico. Dr Sergio Bautista indicated that HIV is concentrated in specific groups, one of which is the population of men who have sex with men (MSM). In addition to a higher prevalence of HIV Dr Bautista indicated that MSM beared an elevated perception of stigma and discrimination. This study sought to address the potential problem of endogeneity in this association due to omitted variables, measurement error or simultaneity if use of health care services influenced their perception of stigma and discrimination.
Data used in this study came from a seroprevalence survey of a representative sample of MSM that gathers in meeting places (2011) and from the Mexican National Survey on Discrimination (2010) using a two-stage model with instrumental variables. The study concluded that a greater perception of stigma was associated with a lower probability for getting tested for HIV, due both to the implicit disclosure of sexual preference provided by the testing and also to the stigma associated with HIV, particularly in a high-risk population such as MSM. 
PARALLEL SESSION F Speakers
Highlights
Modelling shows that condoms remain one of the most cost-effective HIV prevention interventions, and although condom use is not well understood, scale up of the global HIV response must continue to focus on increasing distribution and changing attitudes towards condom use. Presentations also focused on the importance of ART in the HIV response. In Malawi, modelling showed that investing in the health benefits of ART was highly cost effective, and in South Africa, community based ART programmes could help to decrease the burden of treatment and care on healthcare workers, although these would need to be designed carefully according to the needs of clients and keeping in mind the availability and skills of healthcare workers to manage such programmes. The Namibia Investment Case showed how a small increase in funding and increased focus on efficiency could help reach the UNAIDS Fast Track targets, and incur the lowest costs in the long term.
Critical assessment
Understanding how to gain efficiency and ensure the cost-effectiveness of interventions is vital in an era of declining donor funding for HIV, increasing competition for domestic funding for health under the new SDG agenda, and increased fiscal pressure in countries in Southern and Eastern Africa. However, increasing efficiencies will require an initial commitment of resources to see gains in the future. Increasing cost-effectiveness is vital for the long term sustainability of the HIV response and the individual interventions of which it is comprised. However, short term sacrifices must be made to restructure and strengthen systems and develop implementation plans to ensure the HIV response is optimal and reactive to changes in evidence as interventions evolve. Cost-effectiveness analyses must be translated into policy and implementation if they are to see maximum impact in increasing the sustainability of the HIV response.
